Tumor targeted self-synergistic nanoplatforms for arsenic-sensitized photodynamic therapy

Area of Science:

• Biomedical Research
• Nanotechnology
• Oncology

Background:

• Traditional antitumor strategies face limitations due to non-specificity and abnormal tumor microenvironments, leading to poor efficacy and severe side effects.
• Hypoxic tumors present a significant challenge in cancer therapy, requiring novel treatment approaches.

Purpose of the Study:

• To develop a tumor-targeted self-synergistic nanoplatform (PAO@PCN@HA) for chemotherapy-sensitized photodynamic therapy (PDT) against hypoxic tumors.
• To investigate the potential of phenylarsine oxide (PAO) and PCN-224 in a combined therapeutic strategy.

Main Methods:

• Efficient loading of phenylarsine oxide (PAO) into porphyrinic metal-organic framework (PCN-224).
• Surface modification with hyaluronic acid (HA) for targeted drug delivery.
• In vitro and in vivo evaluations of the PAO@PCN@HA nanoplatform's efficacy and toxicity.

Main Results:

• The PAO@PCN@HA nanoplatform demonstrated efficient drug delivery and reduced side effects of PAO.
• PAO induced apoptosis and modulated the tumor microenvironment by mitigating hypoxia and consuming glutathione (GSH), enhancing PDT efficacy.
• Both in vitro and in vivo studies confirmed effective self-synergy and low systemic toxicity in hypoxic tumor therapy.

Conclusions:

• The PAO@PCN@HA nanoplatform offers a promising self-synergistic approach for treating hypoxic tumors.
• Integration of microenvironment modulation with targeted therapy provides a new strategy for arsenic-based antitumor development.
• This approach holds potential for future clinical applications in cancer treatment.